These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 20962509

  • 1. Gender dichotomy in long term growth trajectories of children with 21-hydroxylase deficiency congenital adrenal hyperplasia.
    Patel L, Chandrashekhar SR, Gemmell I, O'Shea E, Jones J, Banerjee I, Amin R, Clayton P.
    Horm Res Paediatr; 2011; 75(3):206-12. PubMed ID: 20962509
    [Abstract] [Full Text] [Related]

  • 2. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Völkl TM, Simm D, Beier C, Dörr HG.
    Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
    [Abstract] [Full Text] [Related]

  • 3. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
    Bonfig W, Schwarz HP.
    Horm Res Paediatr; 2011 Jan; 75(4):264-8. PubMed ID: 21196707
    [Abstract] [Full Text] [Related]

  • 4. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
    Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C.
    Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
    [Abstract] [Full Text] [Related]

  • 5. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study.
    Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, Kovács J, Waldhauser F, Frisch H, MEWPE-CAH Study Group.
    Horm Res; 2001 Nov; 55(4):161-71. PubMed ID: 11598369
    [Abstract] [Full Text] [Related]

  • 6. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
    Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP.
    J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
    [Abstract] [Full Text] [Related]

  • 7. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.
    Roche EF, Charmandari E, Dattani MT, Hindmarsh PC.
    Clin Endocrinol (Oxf); 2003 May; 58(5):589-96. PubMed ID: 12699440
    [Abstract] [Full Text] [Related]

  • 8. Long-term prednisone versus hydrocortisone treatment in children with classic Congenital Adrenal Hyperplasia (CAH) and a brief review of the literature.
    Ahmed SEAM, Soliman AT, Ramadan MA, Elawwa A, Abugabal AMS, Emam MHA, De Sanctis V.
    Acta Biomed; 2019 Sep 06; 90(3):360-369. PubMed ID: 31580328
    [Abstract] [Full Text] [Related]

  • 9. Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age.
    Sarafoglou K, Forlenza GP, Yaw Addo O, Kyllo J, Lteif A, Hindmarsh PC, Petryk A, Gonzalez-Bolanos MT, Miller BS, Thomas W.
    Clin Endocrinol (Oxf); 2017 May 06; 86(5):708-716. PubMed ID: 28199739
    [Abstract] [Full Text] [Related]

  • 10. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
    Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB.
    J Pediatr Endocrinol Metab; 2012 May 06; 25(9-10):977-81. PubMed ID: 23426829
    [Abstract] [Full Text] [Related]

  • 11. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.
    Bonfig W, Schmidt H, Schwarz HP.
    Horm Res Paediatr; 2011 May 06; 75(1):32-7. PubMed ID: 20714115
    [Abstract] [Full Text] [Related]

  • 12. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
    Pijnenburg-Kleizen KJ, Thomas CMG, Otten BJ, Roeleveld N, Claahsen-van der Grinten HL.
    J Pediatr Endocrinol Metab; 2019 Oct 25; 32(10):1055-1063. PubMed ID: 31573958
    [Abstract] [Full Text] [Related]

  • 13. Molecular testing in congenital adrenal hyperplasia due to 21α-hydroxylase deficiency in the era of newborn screening.
    Sarafoglou K, Lorentz CP, Otten N, Oetting WS, Grebe SK.
    Clin Genet; 2012 Jul 25; 82(1):64-70. PubMed ID: 21534945
    [Abstract] [Full Text] [Related]

  • 14. Treatment of congenital adrenal hyperplasia in children aged 0-3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure.
    Neumann U, van der Linde A, Krone RE, Krone NP, Güven A, Güran T, Elsedfy H, Poyrazoglu S, Darendeliler F, Bachega TASS, Balsamo A, Hannema SE, Birkebaek N, Vieites A, Thankamony A, Cools M, Milenkovic T, Bonfig W, Costa EC, Atapattu N, de Vries L, Guaragna-Filho G, Korbonits M, Mohnike K, Bryce J, Ahmed SF, Voet B, Blankenstein O, Claahsen-van der Grinten HL.
    Eur J Endocrinol; 2022 Apr 11; 186(5):587-596. PubMed ID: 35290211
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
    Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SM, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM.
    Arch Dis Child; 2002 Aug 11; 87(2):139-44. PubMed ID: 12138066
    [Abstract] [Full Text] [Related]

  • 16. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
    Aycan Z, Ocal G, Berberoglu M, Cetinkaya E, Adiyaman P, Evliyaoglu O.
    J Pediatr Endocrinol Metab; 2006 Mar 11; 19(3):245-51. PubMed ID: 16607925
    [Abstract] [Full Text] [Related]

  • 17. Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
    Sellick J, Aldridge S, Thomas M, Cheetham T.
    J Pediatr Endocrinol Metab; 2018 Sep 25; 31(9):1019-1022. PubMed ID: 30173205
    [Abstract] [Full Text] [Related]

  • 18. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
    Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP.
    J Clin Endocrinol Metab; 2009 Oct 25; 94(10):3882-8. PubMed ID: 19622620
    [Abstract] [Full Text] [Related]

  • 19. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience.
    Hoepffner W, Kaufhold A, Willgerodt H, Keller E.
    Horm Res; 2008 Oct 25; 70(1):42-50. PubMed ID: 18493149
    [Abstract] [Full Text] [Related]

  • 20. Sodium Chloride Supplementation Is Not Routinely Performed in the Majority of German and Austrian Infants with Classic Salt-Wasting Congenital Adrenal Hyperplasia and Has No Effect on Linear Growth and Hydrocortisone or Fludrocortisone Dose.
    Bonfig W, Roehl F, Riedl S, Brämswig J, Richter-Unruh A, Fricke-Otto S, Hübner A, Bettendorf M, Schönau E, Dörr H, Holl RW, Mohnike K.
    Horm Res Paediatr; 2018 Oct 25; 89(1):7-12. PubMed ID: 29073619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.